BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 16950620)

  • 1. N',2-diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists.
    Elliott JM; Carling RW; Chambers M; Chicchi GG; Hutson PH; Jones AB; MacLeod A; Marwood R; Meneses-Lorente G; Mezzogori E; Murray F; Rigby M; Royo I; Russell MG; Sohal B; Tsao KL; Williams B
    Bioorg Med Chem Lett; 2006 Nov; 16(22):5748-51. PubMed ID: 16950620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N',2-diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists II.
    Elliott JM; Carling RW; Chicchi GG; Crawforth J; Hutson PH; Jones AB; Kelly S; Marwood R; Meneses-Lorente G; Mezzogori E; Murray F; Rigby M; Royo I; Russell MG; Shaw D; Sohal B; Tsao KL; Williams B
    Bioorg Med Chem Lett; 2006 Nov; 16(22):5752-6. PubMed ID: 16950617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and SAR of sulfoxide substituted carboxyquinolines as NK3 receptor antagonists.
    Xiong H; Kang J; Woods JM; McCauley JP; Koether GM; Albert JS; Hinkley L; Li Y; Gadient RA; Simpson TR
    Bioorg Med Chem Lett; 2011 Mar; 21(6):1896-9. PubMed ID: 21320776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Senktide-induced gerbil foot tapping behaviour is blocked by selective tachykinin NK1 and NK3 receptor antagonists.
    Sundqvist M; Kristensson E; Adolfsson R; Leffler A; Ahlstedt I; Engberg S; Drmota T; Sigfridsson K; Jussila R; de Verdier J; Novén A; Johansson A; Påhlman I; von Mentzer B; Lindström E
    Eur J Pharmacol; 2007 Dec; 577(1-3):78-86. PubMed ID: 17920583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-activity relationship studies on N'-aryl carbohydrazide P2X7 antagonists.
    Nelson DW; Sarris K; Kalvin DM; Namovic MT; Grayson G; Donnelly-Roberts DL; Harris R; Honore P; Jarvis MF; Faltynek CR; Carroll WA
    J Med Chem; 2008 May; 51(10):3030-4. PubMed ID: 18438986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virtual screening to identify novel antagonists for the G protein-coupled NK3 receptor.
    Geldenhuys WJ; Kuzenko SR; Simmons MA
    J Med Chem; 2010 Nov; 53(22):8080-8. PubMed ID: 21047106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New quinoline NK3 receptor antagonists with CNS activity.
    Smith PW; Wyman PA; Lovell P; Goodacre C; Serafinowska HT; Vong A; Harrington F; Flynn S; Bradley DM; Porter R; Coggon S; Murkitt G; Searle K; Thomas DR; Watson JM; Martin W; Wu Z; Dawson LA
    Bioorg Med Chem Lett; 2009 Feb; 19(3):837-40. PubMed ID: 19117759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of a dipeptide chemical library in the development of non-peptide tachykinin NK3 receptor selective antagonists.
    Boden P; Eden JM; Hodgson J; Horwell DC; Hughes J; McKnight AT; Lewthwaite RA; Pritchard MC; Raphy J; Meecham K; Ratcliffe GS; Suman-Chauhan N; Woodruff GN
    J Med Chem; 1996 Apr; 39(8):1664-75. PubMed ID: 8648606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of 2-(4-biphenylyl)quinoline-4-carboxylate and carboxamide analogs. New human neurokinin-3 (hNK-3) receptor antagonists.
    Saudi MN; Rostom SA; Fahmy HT; El Ashmawy IM
    Arch Pharm (Weinheim); 2003 Jun; 336(3):165-74. PubMed ID: 12822182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2-Phenyl-4-quinolinecarboxamides: a novel class of potent and selective non-peptide competitive antagonists for the human neurokinin-3 receptor.
    Giardina GA; Sarau HM; Farina C; Medhurst AD; Grugni M; Foley JJ; Raveglia LF; Schmidt DB; Rigolio R; Vassallo M; Vecchietti V; Hay DW
    J Med Chem; 1996 Jun; 39(12):2281-4. PubMed ID: 8691422
    [No Abstract]   [Full Text] [Related]  

  • 11. Lead identification of 2-iminobenzimidazole antagonists of the chemokine receptor CXCR3.
    Hayes ME; Breinlinger EC; Wallace GA; Grongsaard P; Miao W; McPherson MJ; Stoffel RH; Green DW; Roth GP
    Bioorg Med Chem Lett; 2008 Apr; 18(7):2414-9. PubMed ID: 18337097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of species-related differences in the pharmacology of tachykinin NK receptors 1, 2 and 3.
    Leffler A; Ahlstedt I; Engberg S; Svensson A; Billger M; Oberg L; Bjursell MK; Lindström E; von Mentzer B
    Biochem Pharmacol; 2009 May; 77(9):1522-30. PubMed ID: 19426690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and insecticidal activity of benzoheterocyclic analogues of N'-benzoyl-N-(tert-butyl)benzohydrazide: Part 3. Modification of N-tert-butylhydrazine moiety.
    Sawada Y; Yanai T; Nakagawa H; Tsukamoto Y; Tamagawa Y; Yokoi S; Yanagi M; Toya T; Sugizaki H; Kato Y; Shirakura H; Watanabe T; Yajima Y; Kodama S; Masui A
    Pest Manag Sci; 2003 Jan; 59(1):49-57. PubMed ID: 12558099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Piperazinyl oxime ethers as NK-1 receptor antagonists.
    van den Hoogenband A; van Maarseveen JH; McCreary AC; Mulder AT; van Scharrenburg GJ; van Stuivenberg HH; Zethof TJ; Zijta B; Iwema Bakker WI
    Bioorg Med Chem Lett; 2006 Feb; 16(4):1045-8. PubMed ID: 16289817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of substituted 6-amino-4-phenyltetrahydroquinoline derivatives: potent antagonists for the follicle-stimulating hormone receptor.
    van Straten NC; van Berkel TH; Demont DR; Karstens WJ; Merkx R; Oosterom J; Schulz J; van Someren RG; Timmers CM; van Zandvoort PM
    J Med Chem; 2005 Mar; 48(6):1697-700. PubMed ID: 15771412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and synthesis of a novel, achiral class of highly potent and selective, orally active neurokinin-1 receptor antagonists.
    Hoffmann T; Bös M; Stadler H; Schnider P; Hunkeler W; Godel T; Galley G; Ballard TM; Higgins GA; Poli SM; Sleight AJ
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1362-5. PubMed ID: 16332435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis of new 4-heteroaryl-2-phenylquinolines and their pharmacological activity as NK-2/NK-3 receptor ligands.
    Borioni A; Mustazza C; Sestili I; Sbraccia M; Turchetto L; Del Giudice MR
    Arch Pharm (Weinheim); 2007 Jan; 340(1):17-25. PubMed ID: 17206605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and development of a new class of potent, selective, orally active oxytocin receptor antagonists.
    Quattropani A; Dorbais J; Covini D; Pittet PA; Colovray V; Thomas RJ; Coxhead R; Halazy S; Scheer A; Missotten M; Ayala G; Bradshaw C; De Raemy-Schenk AM; Nichols A; Cirillo R; Tos EG; Giachetti C; Golzio L; Marinelli P; Church DJ; Barberis C; Chollet A; Schwarz MK
    J Med Chem; 2005 Dec; 48(24):7882-905. PubMed ID: 16302826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis, biological assessment and molecular modeling of new dihydroquinoline-3-carboxamides and dihydroquinoline-3-carbohydrazide derivatives as cholinesterase inhibitors, and Ca channel antagonists.
    Tomassoli I; Ismaili L; Pudlo M; de Los Ríos C; Soriano E; Colmena I; Gandía L; Rivas L; Samadi A; Marco-Contelles J; Refouvelet B
    Eur J Med Chem; 2011 Jan; 46(1):1-10. PubMed ID: 21111515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of peristalsis by NK3 receptor antagonism in guinea-pig isolated ileum is revealed as intraluminal pressure is raised.
    Sanger GJ; Tuladhar BR; Brown J; Aziz E; Sivakumar D; Furness JB
    Auton Autacoid Pharmacol; 2007 Apr; 27(2):105-11. PubMed ID: 17391280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.